Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zugui Zhang

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
British Journal of Anaesthesia|June 4, 2021
Perioperative dexmedetomidine and 5-year survival in patients undergoing cardiac surgeryKe Peng, Yue-Ping Shen, Yao-Yu Ying, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patientsWilliam S Weintraub, William E Boden, Zugui Zhang, et al.
The Lancet. Public Health|December 3, 2022
The burden of cardiovascular disease attributable to high systolic blood pressure across China, 2005-18: a population-based studyXue Cao, Zhenping Zhao, Yuting Kang, et al.
Journal of the American College of Cardiology|January 10, 2015
Cost-effectiveness of revascularization strategies: the ASCERT studyZugui Zhang, Paul Kolm, Maria V Grau-Sepulveda, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable anginaZugui Zhang, Paul Kolm, William E Boden, et al.
Journal of the American Heart Association|December 29, 2023
Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United StatesWilliam S Weintraub, Deepak L Bhatt, Zugui Zhang, et al.
Journal of the American Heart Association|May 6, 2021
Estimating Systolic Blood Pressure Intervention Trial Participant Posttrial Survival Using Pooled Epidemiologic Cohort DataBrandon K Bellows, Yiyi Zhang, Zugui Zhang, et al.
JAMA Network Open|February 14, 2022
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin TreatmentWilliam S Weintraub, Deepak L Bhatt, Zugui Zhang, et al.
Journal of the American College of Cardiology|April 23, 2021
Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse EventsAdam P Bress, Tom Greene, Catherine G Derington, et al.
The New England Journal of Medicine|August 24, 2017
Cost-Effectiveness of Intensive versus Standard Blood-Pressure ControlAdam P Bress, Brandon K Bellows, Jordan B King, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
British Journal of Anaesthesia|June 4, 2021
Perioperative dexmedetomidine and 5-year survival in patients undergoing cardiac surgeryKe Peng, Yue-Ping Shen, Yao-Yu Ying, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patientsWilliam S Weintraub, William E Boden, Zugui Zhang, et al.
The Lancet. Public Health|December 3, 2022
The burden of cardiovascular disease attributable to high systolic blood pressure across China, 2005-18: a population-based studyXue Cao, Zhenping Zhao, Yuting Kang, et al.
Journal of the American College of Cardiology|January 10, 2015
Cost-effectiveness of revascularization strategies: the ASCERT studyZugui Zhang, Paul Kolm, Maria V Grau-Sepulveda, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable anginaZugui Zhang, Paul Kolm, William E Boden, et al.
Journal of the American Heart Association|December 29, 2023
Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United StatesWilliam S Weintraub, Deepak L Bhatt, Zugui Zhang, et al.
Journal of the American Heart Association|May 6, 2021
Estimating Systolic Blood Pressure Intervention Trial Participant Posttrial Survival Using Pooled Epidemiologic Cohort DataBrandon K Bellows, Yiyi Zhang, Zugui Zhang, et al.
JAMA Network Open|February 14, 2022
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin TreatmentWilliam S Weintraub, Deepak L Bhatt, Zugui Zhang, et al.
Journal of the American College of Cardiology|April 23, 2021
Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse EventsAdam P Bress, Tom Greene, Catherine G Derington, et al.
The New England Journal of Medicine|August 24, 2017
Cost-Effectiveness of Intensive versus Standard Blood-Pressure ControlAdam P Bress, Brandon K Bellows, Jordan B King, et al.
Pageof 8